billHR8766•Event Tuesday, May 12, 2026Analyzed

Deal Death, Face Death Act

Neutral

Summary

HR 8766 is an early-stage bill introduced by Rep. Chip Roy that would mandate the death penalty for knowingly dealing fentanyl where death results. It has been referred to two committees with no further action. No market impact is identifiable at this stage as the bill authorizes no spending, creates no contracts, and targets criminal penalties only.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

1.HR 8766 imposes the death penalty for fentanyl dealing resulting in death; no spending or market mechanism exists.
2.The bill is at the earliest legislative stage — referred to two committees with no further actions.
3.No publicly traded companies are impacted; zero funds are authorized or appropriated.

Market Implications

No market implications. HR 8766 is a criminal penalty bill with no authorized spending, no contracts, and no regulatory changes affecting public companies. The energy and healthcare sectors listed in the SEC filing data have no connection to this legislation.

Full Analysis

1) What happened: Rep. Chip Roy (R-TX-21) introduced HR 8766, the 'Deal Death, Face Death Act,' on May 12, 2026. The bill amends the Controlled Substances Act to mandate the death penalty for any person who knowingly deals fentanyl when death results from its use. It was referred to the House Judiciary and Energy & Commerce Committees. Status: early-stage, no hearings or markup scheduled. 2) Money trail: The bill authorizes zero dollars. It imposes a criminal penalty — the death penalty — not a spending program, tax credit, or procurement authorization. No contracts, grants, or subsidies flow from its passage. The fines referenced ($2M/$10M) are penalties paid to the U.S. Treasury, not new program funding. 3) Winners and losers: This bill does not affect any publicly traded company's revenue, costs, or competitive position. It targets individual criminal liability for drug dealers. No pharmaceutical manufacturer, healthcare provider, or law enforcement contractor is mentioned or directly affected. The fentanyl supply chain is illicit; legitimate opioid manufacturers (e.g., $JNJ, $PFE) are not named or impacted. 4) Competitive landscape: Not applicable. No market sector is structurally affected. 5) Timeline: The bill must pass the House Judiciary Committee, House floor, Senate (with companion bill), and be signed by the President. As an early-stage referral with no Senate companion, passage in the 119th Congress is speculative and distant.

Connected Signals

Matched on shared policy language across AI analyses, with ticker & timing weight

BillStrong LinkNeutral

Federal Carjacking Enforcement Act

Shared: Penalty Death · Death · Criminal28% match